A b s t r a c t
We measured the frequency and outcome of cervical cancer prevention failures that occurred in the Papanicolaou (Pap) and colposcopy testing phases involving 1,646,580 Pap tests in 4 American hospital systems between
The success of cervical cancer prevention depends on optimizing the performance of a number of unique testing steps. Much of the medical literature has focused on the Papanicolaou (Pap) test screening portion of cervical cancer prevention, and numerous studies have evaluated the accuracy of the Pap test and investigated the root cause of Pap test failures. [1] [2] [3] Despite the well-recognized success of the Pap test in reducing the incidence and mortality rates of cervical cancer, 1, 2 the Pap test portion of cervical cancer prevention services has been the phase most radically transformed by new technologies and the effect of governmental regulations. [4] [5] [6] [7] [8] [9] Pap test screening failures may occur in any testing phase from ordering, performing, processing, interpreting, reporting, and then acting on the result of a test. Yet, if cervical cancer prevention is viewed from the perspective of the total testing process, 10 the steps of initial patient recruitment, screening, and follow-up also are vitally important for cancer prevention. It is well documented that the majority of women in whom cervical cancer develops never had a Pap test or did not have a recent Pap test. 11, 12 The frequency and the effect of failures in phases of the cervical cancer prevention testing cycle beyond the initial screening examination have been less well studied.
One method of detecting Pap test failures is by using the cytologic-histopathologic (CH) correlation method by comparing the Pap test and follow-up cervical biopsy diagnoses. 7, 13, 14 The College of American Pathologists and others documented the usefulness of CH correlation in identifying overall performance and error-prone steps in Pap testing. 13, 14 However, CH correlation also may be used to detect failures in the follow-up colposcopy testing cycle. 13 In the ASCUS-LSIL [Atypical Squamous Cells of Undetermined Significance-LowGrade Squamous Intraepithelial Lesion] Triage Study (ALTS), Ferris et al 15 reported that the mean colposcopist sensitivity for detecting cervical intraepithelial neoplasia (CIN) 2 or 3 was lower than expected, indicating that failures in the colposcopy phase of testing are not uncommon.
Our primary goal in this study was to establish a baseline level of cervical cancer screening failures occurring in the Pap test and the colposcopy phases of testing using the CH correlation method. Our approach considered that each test in the prevention process was unique and that each false-negative or false-positive diagnosis had the potential to result in unnecessary delay or overtesting and/or overtreatment or undertreatment. We measured the frequency and impact of false-negative and false-positive Pap test and colposcopy biopsy diagnoses on patient care.
Materials and Methods

Cervical Cancer Prevention
In most developed nations, cervical cancer prevention involves the successful performance of several distinct tests, [4] [5] [6] [7] [8] [9] 16 and, conceptually, these tests conjointly may be viewed as a total testing process. 10 Women undergo a screening test, such as a Pap test, follow-up colposcopy for specific Pap test epithelial cell abnormality diagnoses, 4,17 and a second clinic visit for lesion excision for specific histopathologic diagnoses. [18] [19] [20] The implementation of new Pap test technologies, screening intervals, and follow-up protocols was variably standardized during our study time frame. In general, women who had a Pap test diagnosis of LSIL; high-grade SIL (HSIL); atypical glandular cells; cancer, atypical squamous cells (ASC), cannot exclude HSIL; or ASC, undetermined significance (ASC-US) (with a positive high-risk human papilloma virus [HPV] DNA test result) were referred for colposcopy. 6, 17 
Study Population
The study population included all women who received a Pap test between January 1, 1998, and December 31, 2004 , in 4 health care systems. This study is part of a larger project funded by the Agency for Healthcare Research and Quality and by the Centers for Disease Control and Prevention as a means to study and improve patient safety in diagnostic testing and screening. 13 The health care systems were the University of Pittsburgh Medical Center, Pittsburgh, PA; Henry Ford Health System, Detroit, MI; Western Pennsylvania Hospital, Pittsburgh; and the University of Iowa Healthcare, Iowa City; they were deidentified for the purposes of this study. All sites obtained institutional review board approval for project performance. The 4 institutions adopted liquid-based cytology between 2000 and 2004 and high-risk HPV DNA testing for ASC-US diagnoses between 2002 and 2004. Our goal was not to specifically study the implementation of these technologies because they were introduced variably and gradually.
Definitions of Discrepancy and Test Failure
We defined a discrepancy as a difference between the cytologic and histopathologic diagnoses that indicated the presence or absence of a pathologic entity or a definite difference in the degree to which the pathologic condition was judged to be present. 11 Cytologic and histopathologic diagnostic schema are different, and we developed a scaled hierarchy of categories to determine if a discrepancy occurred ❚Table 1❚. 13 We used the 2001 Bethesda System to classify Pap test results and the CIN system to classify histopathologic diagnoses. 17, 21 The CH correlation discrepancy proportion depends on the method of case detection. 13 Correlation processes were standardized at the 4 study sites in 2002 ❚Table 2❚, and the effectiveness of cervical cancer screening before (n = 1,083,221 Pap tests) and after (n = 563,359 Pap tests) standardization was evaluated separately. We defined a test failure as a 2-step or greater discrepancy, because in most cases, one of the diagnoses did not accurately describe the presence or absence of a disease in a patient. 13, 21, 22 We examined only 2-step or greater discrepancies because 1-step discrepancies were exceedingly common, generally were associated with minimal impact on clinical outcome, and were associated with poorly reproducible adjudication of failure cause. 13 Thus, some 1-step differences with clinical import (eg, HSIL Pap test and CIN 1 histopathologic specimen) were not examined.
The review pathologist performed a root cause analysis by reviewing all microscopic slides associated with the discrepant Pap test and histopathologic biopsy results. The pathologist then adjudicated if the failure was secondary to the preanalytic (sampling) or analytic (screening or interpretation) phases of the Pap or colposcopy testing cycles. 14 An analytic failure was a failure in diagnostic categorization by the individual who originally screened or examined the case. A preanalytic failure was a failure in which diagnostic material was not present on the slides of one case and present on the slides of the other. Our previous work has shown that traditional methods of adjudication of test failure root cause exhibited moderate to low reproducibility. However, this adjudication method may be used as a first step in exploring more detailed analysis of failure cause.
We separately examined the relationship between specific diagnostic categorical differences and impact on care for the following:
1. High-grade lesions (adenocarcinoma in situ and HSIL) and cancers (squamous carcinoma and endocervical adenocarcinoma) not detected by Pap testing. The ability of the Pap test to detect some glandular lesions is controversial, 23, 24 and, therefore, discrepant cases of endometrial vault adenocarcinomas were excluded from our analysis. Because CH correlation traditionally is not used to compare Pap test and histopathologic diagnoses with long intervals between specimen procurement, 14 we excluded women who had specimens procured more than 6 months apart (eg, false-negative Pap test results based on a 1-year look back). We determined the number of women who had a benign Pap test result with cancer or high-grade lesion follow-up result.
2. High-grade lesions and cancers not detected in histopathologic specimens when the Pap test result was abnormal. Because high-grade lesions and cancers are unlikely to regress in an interval of 6 months or less, most of these discrepancies were secondary to failures in the colposcopy testing phase.
3. Disease misclassification on Pap tests and histopathologic specimens, excluding specimens from women who had a missed cancer or high-grade lesion. This number represented the diagnostic noise in the screening system and was the number of underdiagnosed or overdiagnosed lesions (excluding underdiagnosed cancers and high-grade lesions). We recognized LSIL disease regression complicated the test failure adjudication process. 25 We evaluated the cases of women who had an original and review LSIL Pap test and follow-up benign histopathologic diagnoses in 2 ways. First, we considered the failure as a preanalytic colposcopy failure regardless of postcolposcopy follow-up because this discrepant pair resulted in at least clinical confusion and patient anxiety. Clinicians did not know whether the LSIL actually had regressed and responded variably. Second, we only considered the cases of women who had an abnormal Pap test or histopathologic biopsy follow-up as preanalytic failures with the remainder falling in an indeterminate failure class.
Impact on Patient Care
We performed clinical record review on all cases with Pap test-histopathologic specimen discrepancies that had original or review diagnoses of HSIL/CIN 2 or greater and a random sample of 10% of all discrepancies that had original or review diagnoses of less than HSIL/CIN 2. 13 A 10% clinical record review was performed on the latter subset because preliminary studies showed that women with these discrepancies had very similar assessments of outcomes and that the annual volume of these discrepancies was prohibitively large. We extrapolated the reviewed sample proportions of outcomes to all unreviewed cases. The clinical record reviewer recorded additional tests ordered, additional treatment protocols initiated, morbidity or mortality related to additional tests or treatments, and delays in diagnosis. A pathologist assessed the clinical impact of the discrepancies using the categories shown in ❚Table 3❚. This scheme was based on error impact schema previously published in the medical literature. 13, 26, 27 We note that other classification schemes use the term harm to indicate a negative clinical outcome that may be graded in degree. 26, 27 
Data Analysis
All data analyses were performed using SPSS software (version 14, SPSS, Chicago, IL). Data initially were analyzed descriptively. Discrepant case frequencies were calculated for different categories of initial Pap test or histopathologic diagnoses. Proportions of discrepant cases occurring during specific intervals were calculated as n/d, with n the number of discrepant cases and d the total number of Pap tests examined during the same interval. Appropriate denominator values were retrieved from existing electronic laboratory information systems using query tools designed to extract Pap test workload data.
Differences in discrepancy proportions were examined by using the Fisher exact test or the χ 2 test. Statistical significance was assumed at a P value of .05 or less.
Discrepant Pap test-histopathologic case pairs were obtained concurrently or nonconcurrently. For nonconcurrent discrepant case pairs, the Pap test was done during a separate clinic or office visit before colposcopy. Concurrently obtained discrepant specimens were obtained during the same colposcopy procedure. The practice of obtaining a Pap test specimen at the time of colposcopy with biopsy was variable; therefore, we performed separate analyses including and excluding these data.
Results
The number of all and nonconcurrent testing failures is shown in ❚Table 4❚ and ❚Table 5❚, respectively. Standardized CH correlation resulted in greater discrepancy detection compared with nonstandardized methods (P < .001). Excluding concurrent case pairs, the proportion of women who had a Pap test and a CH correlation discrepancy was 0.5% (or 1 in 204 Pap tests); 0.2% of the total (1 in 596 Pap tests) had a discrepancy secondary to an analytic failure. In the standardized time frame, more women had a discrepancy secondary to a colposcopic failure compared with a Pap test failure. 
The number of nonconcurrent false-negative Pap test results (original Pap test diagnosed as no evidence of intraepithelial lesion or malignancy [NILM]
) and histopathologic specimens (original histopathologic specimen diagnosed as benign) is shown in ❚Table 6❚. CH correlation standardization resulted in increased detection of discrepancies (P < .001). In the poststandardized cohort, only 3 squamous cell carcinomas (5.33 × 10 -4 % or 1 in 187,786 Pap tests) had an NILM Pap test result, and none was adjudicated as an analytic failure. The proportion of women who had an adenocarcinoma diagnosis on a histopathologic specimen and an NILM Pap test result was far more common (0.005% or 1 in 19,426 Pap tests with 1 in 46,947 Pap tests having an analytic failure). As a result of CH correlation standardization, the number of benign histopathologic specimens with LSIL Pap test results increased by 3-fold, and 75% of these discrepancies were secondary to a preanalytic colposcopy failure.
The majority of false-negative colposcopy failures (bottom of Table 6 ) were associated with an LSIL Pap test result. In this analysis, all cases in which the Pap diagnosis was adjudicated as LSIL and the colposcopy diagnosis was not adjudicated as an analytic failure were considered preanalytic colposcopy failures. Review of the follow-up of these cases showed that 61.0% had a follow-up abnormal Pap test or histopathologic diagnosis, 30.5% had no abnormal diagnoses, and 8.5% were lost to follow-up. Thus, 33.3% of women with follow-up may have had LSIL regression before colposcopy, reducing the total number of false-negative histopathologic diagnoses from 2,104 to 1,710 cases.
The impact of failures is shown in ❚Table 7❚. We separately examined the impact of 2 discrepancy categories: HSIL/CIN 2+ and LSIL/CIN 1 and lower. In the pre-CH correlation standardized cohorts, more women had no-harm outcomes for all discrepancy categories. In the standardized cohorts, there was a shift of outcome classification from no harm to near miss. For the nonconcurrent and concurrent HSIL/CIN 2+ groups, negative outcomes were observed in 70.8% to 22.7% of all failures, and severe negative outcomes were identified in a small minority of cases. In the LSIL/CIN 1 or lower groups, negative outcomes were identified in 63.9% and 15.1% of the nonconcurrent and concurrent discrepant cases, respectively; the negative outcome was generally minimal or mild.
Discussion
These correlation failure data show that cervical cancer prevention services are highly effective in preventing squamous cancers, less effective in preventing adenocarcinomas, and associated with a relatively large yearly number of lowgrade test failures with women having an excessive number of repeated Pap tests, colposcopic procedures with unnecessary biopsies, anxiety, and delays in diagnosis. These data also indicate that the majority of test failures, particularly failures in diagnosing high-grade lesions, occur more frequently in the colposcopy rather than the initial Pap testing cycle of cervical cancer prevention.
The level of squamous cancer prevention produced by the American screening system is remarkable, and our data corroborate the findings of numerous previously published studies. 1, 2, 16, 18, 19 28 occur in more than 285,000 women. Many American laboratories do not track or follow up the majority of CH correlation discrepancies, 29 and the focus has been on increasing Pap test squamous intraepithelial lesion detection through Pap test technologies 5, 6, 8, 9 and regulation 7 and not on preventing other failure types, particularly those related to colposcopy failures.
Determining the cause of test failure has been challenging because of observer bias and lack of adequate tools and frontline skills to perform root cause analysis. Not unexpectedly, our consortium found that the cause of test failures generally was multifactorial and secondary to a host of factors, including organizational structure and lack of standardization, not simply practitioner lack of skill. 30, 31 Some pathologists understandably have advocated a medical-legal, panel-review-based approach to CH correlation, 32 although this process has resulted in a measure of reproducibility of adjudicated cause rather than a focus on the interplay of contributing factors. We found that many test failures were secondary to poor specimen interpretability composed of factors in specimen collection, processing, and diagnostic interpretation. 30 Adjudication of test failure into preanalytic or analytic steps and Pap test or colposcopy phases serves as a basis for quality improvement study and is not meant to be punitive. 13, 30 Our data indicate that phases other than the Pap test interpretation phase need to be addressed from a quality improvement perspective.
Interestingly, cervical cancer screening was far less effective in the prevention of endocervical adenocarcinoma than in the prevention of squamous carcinoma. We found that for every 100,000 Pap tests, approximately 5 endocervical adenocarcinomas were missed. Endocervical adenocarcinomas are increasing in incidence, 33 and in the United States, missed adenocarcinomas are becoming an increasing source of litigation. 34 Not all experts believe that the Pap test was designed to detect adenocarcinoma, 35 and they attribute false-negative Pap test results as secondary to patient-related factors. Only rare studies have shown a decrease in mortality due to adenocarcinoma in screened populations. 36 This belief limits quality improvement because our findings indicate that these failures are secondary to combinations of factors, including patient-related factors as a contributing cause.
Our study has several limitations. First, our case selection criteria reduced our discrepancy proportion because we excluded 1-step discordances and cases of women who had a discrepant Pap test-histopathologic specimen separated by more than 6 months. In the United States, the CH correlation method traditionally has been used to evaluate case pairs obtained within a relatively short time of each other. 13, 14 Second, we could not control for preanalytic variation in screening intervals and follow-up protocols, including colposcopy referral rates and performance of concurrent Pap tests with histopathologic biopsy. Because correlation practices were not standardized before 2002 and liquid-based and high-risk HPV technologies were gradually introduced during this time, we were not able to evaluate how technologies affected failure frequency.
We recognize that assessment of the impact of test failure on care was subjective, 37 particularly for women who may have lesions that regressed. 38 However, excluding cases of possible LSIL regression only reduced the overall number of discrepant cases by 393. Some argue that cervical cancer screening may be viewed as a set of tests in which the ultimate goal is the detection of disease rather than the agreement of individual step diagnoses. In contrast, we considered the diagnosis of each individual Pap or histopathologic test as a unique step revealing information that may conflict or concur with the preceding or follow-up test diagnosis. We believe that the individual test approach is a more patient-centric view of safety, and diagnostic discrepancies, at a minimum, may cause confusion and anxiety. An individual test focus also allows for more specific quality improvement targeting.
The relatively high CH correlation discrepancy proportion justifies the development of error reduction interventions in cervical cancer screening and further study of patient preference. Quality improvement in cervical cancer screening to date primarily has not consisted of process improvement and work redesign. Paradoxically, interventions that decrease the false-negative Pap test result proportion may result in higher discrepancy proportions with more women undergoing colposcopy with noncorrelating biopsy results. We note that our error detection system did not evaluate other process breakdowns such as postanalytic recall failures or the preanalytic problem of women who are not screened.
